An examination into the safety and efficacy of Khapregesic®, a Khaya senegalensis preparation, on physical and psychological wellbeing in women experiencing menopausal symptoms: a randomised, double-blind, placebo-controlled trial - Summary - MDSpire
Advertisement
An examination into the safety and efficacy of Khapregesic®, a Khaya senegalensis preparation, on physical and psychological wellbeing in women experiencing menopausal symptoms: a randomised, double-blind, placebo-controlled trial
To assess the safety and efficacy of Khapregesic® in women reporting menopausal symptoms across the transition from perimenopause to post-menopause, specifically focusing on psychological symptoms, sleep disturbances, and fatigue.
Key Findings:
No statistically significant group differences in change scores across primary and secondary outcomes (source needed).
In postmenopausal women, Khapregesic® showed significant improvements in psychological symptoms (p = 0.014), fatigue (p = 0.045), and sleep disturbances (p = 0.024).
No group differences were detected in perimenopausal women.
Khapregesic® was generally well tolerated with mild gastrointestinal symptoms reported.
Interpretation:
Limitations:
The subgroup analyses should be considered tentative (source needed).
The study did not find statistically significant effects in the overall cohort.
Conclusion:
Further research is needed to confirm the findings regarding mood, sleep, and fatigue in post-menopausal women.
Estonian Biobank analysis of more than 67,000 adults challenges assumptions about age and desire, finding men's peak does not align with expected testosterone decline patterns.
A two-marker methylated DNA assay identified endometrial cancer with 96% sensitivity in self-collected vaginal fluid — but prospective validation is needed before it can reduce biopsies in routine care.
